For the quarter ending 2025-09-30, PAVM had -$901K decrease in cash & cash equivalents over the period. -$899K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Gain on deconsolidation of subsidiary | 0 | - |
| Depreciation and amortization expense | 22 | 65 |
| Change in fair value - equity method investment | -4,382 | 10,361 |
| Amortization of common stock payment for vendor service agreement | 52 | 103 |
| Change in fair value - senior secured convertible notes | 100 | 249 |
| Debt extinguishment loss - senior secured convertible note | 0 | -58 |
| Non-cash lease expense | 5 | 6 |
| Accounts receivable | 0 | -15 |
| Prepaid expenses, deposits and current and other assets | -345 | 259 |
| Accounts payable | -47 | -268 |
| Accrued expenses and other current liabilities | -116 | 253 |
| Stock-based compensation | 383 | 1,092 |
| Net income (loss) - before noncontrolling interest (nci) | -6,012 | 6,300 |
| Net cash flows used in operating activities | -896 | -2,759 |
| Decrease in cash due to deconsolidation of subsidiary | 0 | - |
| Proceeds from sale of intellectual property to lucid diagnostics inc | 0 | - |
| Purchase of equipment | 3 | 14 |
| Net cash flows used in investing activities | -3 | -14 |
| Proceeds issue of preferred stock - subsidiary | 0 | 0 |
| Payment senior secured convertible note acceleration floor payments | 0 | 0 |
| Proceeds issue common stock employee stock purchase plan | 0 | 0 |
| Proceeds subsidiary common stock employee stock purchase plan | 0 | 0 |
| Proceeds exercise of stock options issued under equity plan of subsidiary | 0 | 0 |
| Proceeds issue of common stock and pre-funded warrants, net of financing fees | 0 | 2,370 |
| Proceeds issue of common stock - subsidiary, net of financing costs | -2 | 2,490 |
| Payment financing costs debt exchange | 0 | 109 |
| Proceeds issue of common stock - at-the-market facility | 0 | 841 |
| Net cash flows provided by financing activities | -2 | 5,592 |
| Net increase in cash | -901 | 2,819 |
| Cash and cash equivalents at beginning of period | 1,185 | - |
| Cash and cash equivalents at end of period | 3,103 | - |
PAVmed Inc. (PAVM)
PAVmed Inc. (PAVM)